Leprosy: Yes it is in the U.S. and What You Need to Know (N22)
Recorded for 2022 National Conference
Category: 2022 National Conference
, Cert Exam Domain - Assessment
, Cert Exam Domain - Diagnosis
, Cert Exam Domain - Evaluation
, Cert Exam Domain - Planning
, Health Promotion
, Primary Care
, Recent Additions
, Transforming Clinical Practice Initiative (TCPI)
, Wound Care (show less)
This CE activity was recorded for the 2022 AANP National Conference.
|Content Expires:||July 15, 2023 (11:55 p.m. CT)|
CE for this activity will not be available after this date.
| This activity includes closed captioning.|
|Delivery Note: The content for this activity was previously presented during the 2022 AANP National Conference. If you already completed the content of this activity while attending the live or virtual conference, you should not complete this content a second time. Learners should only complete ONE delivery-method to earn credit. Completing multiple delivery options for the same activity is considered duplicate credit for the same content and will not be accepted by regulatory bodies.|
There has been an increase in referrals and consultative requests to the National Hansen’s Disease Program (NHDP) for Hansen’s disease (HD) services in the past three years from advanced practice providers. The NHDP is a 100 year-old program that has been physician-centric when providing education outreach to the health care community. This identified gap in outreach and education to advanced practice providers may delay accurate diagnosis and care to HD patients throughout the country. HD is a chronic but curable infectious disease caused by acid-fast bacilli, Mycobacterium leprae and Mycobacterium lepromatosis (Sharma, et al., 2020). The global prevalence and incidence of HD is highly prevalent in endemic countries such as, Africa, Brazil, India and Indonesia (ALM, 2020; CDC, 2017; WHO, 2019). Although HD is curable, it continues to cause disabilities globally as well as in the United States of America. Worldwide, three million people are estimated to be permanently disabled from complications of HD (Elflien, J., 2021; WHO 2019). Delayed or untreated HD can cause permanent damage to the skin, nerves, limbs and eyes (CDC, 2017; HRSA, 2020; WHO, 2019). Typical skin lesions and classic neuropathy associated with HD are readily recognized in countries where HD is common, but in the U.S., where HD is rare, it can be difficult to diagnose (CDC, 2017; HRSA, 2020). An HD patient in the U.S. sees an average of three healthcare providers before receiving the correct diagnosis. Equipping U.S. healthcare providers with the tools required to manage HD can have a significant impact on addressing knowledge gaps in the area of HD recognition, diagnosis and treatment.
- Recognize, diagnose, and manage clients with HD.
- State signs, symptoms, and treatment recommendations for clients in reactions.
- Identify HD networks and resources throughout the USA.
- State pillars of the Global Leprosy Strategy for Elimination.
CAPT Amy Flynn, DNP
Mary Dudley, DNP
This program was planned in accordance with AANP CE Standards and Policies.
All relevant financial relationships have been mitigated.
This educational activity may contain opinions of the authors from their personal experience. The activity may contain discussion of published and/ or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/ participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
DisclaimerIndividuals who have contributed to the CE Center (content originally from the 2022 AANP National Conference) were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
CE Credit Instructions
- Read this activity description, including objectives and disclosures.
- Complete all educational content:
- OnDemand Presentations: Click the Play button to watch the activity video lecture. To get full credit for the learning activity portion, you must watch all of the video content.
- Click on the Additional Resources button to review all additional materials provided (handouts and any other downloadable resources).
- After completing all educational content, go to the Next Steps button:
- Submit the activity evaluation to receive full AANP CE/Rx credit.
- Click on the Get Certificate button. At the top of the certificate screen, use the provided dropdown menu and select AANP Certificate of Completion.
- A copy of your certificate of completion will display on the screen for you to print or save. A copy of the certificate will also be emailed to you.
- A copy of the certificate will be automatically added to your AANP CE Tracker.
For questions or more information concerning this CE Center activity, contact AANP CE Center Support at firstname.lastname@example.org.
|0.85 Contact Hour(s) of CE,
0.15 of which may be applied towards Pharmacology
Additional CE activities of interest
Antiviral Medications: A Pharmacologic Review (N22)
Common Skin Conditions: Updates in Pharmacology (N22)
Pharmacologic Management of Urologic Infections (N22)
How Does Nutrition and Lifestyle Behaviors Enhance Immunity? (N22)
Pain Management: Compare and Contrast Opioid and Non-Opioid Analgesics (N22)
To Treat or Not to Treat? Antibiotic Stewardship Across the Lifespan (N22)
Cardiovascular Risk Reduction (N22)
Primary Care Management of Atrial Fibrillation (N22)
Immunization Update 2022: What the NP Needs to Know (N22)
Soft-Tissue Masses of the Extremities: Diagnosis, Management and Differential Considerations (N22)
Cutaneous Manifestations of Connective Tissue Disease (N22)
Inflammatory Bowel Disease: What You Need to Know (N22)